As father and daughter, there are many things Dennis Gorden and Becky Nutley share: a contagious smile, the instinct to help others, and a commitment to family, to name a few. But one thing they never imagined they would have in common was a cancer diagnosis. In 2014, routine blood work revealed that Becky Nutley, … Read more
As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and researchers face a new challenge: how to predict a drug’s long-term effectiveness? How to tell, early on, whether one drug is likely to extend patients’ lives more than another? At Dana-Farber’s Jerome Lipper … Read more
A study by Dana-Farber scientists and an international team of researchers could lead to better treatments for patients with smoldering multiple myeloma, a condition that often precedes myeloma.
Advances against multiple myeloma have come at an especially rapid pace, with 10 new therapies approved in just the last 10 years. As a group, their impact “is greater than anything we’ve seen in myeloma,” says Nikhil Munshi, MD, director of Basic and Correlative Science at Dana-Farber’s Jerome Lipper Center for Multiple Myeloma.
A year ago, Kelly Lamphere’s multiple myeloma was not responding to treatment, and her legs were so weakened by the cancer in her bones that she relied on a wheelchair and a walker. Today, because of CAR T-cell therapy, Lamphere’s disease is under control—and she can walk unaided again.
Assessing a multiple myeloma patient’s predicted outcome and risk through genetic analysis can enable tailored treatment for individual patients.
Minimal residual disease negativity – or MRD negativity – is a highly sensitive measure of the effectiveness of therapy for multiple myeloma, a cancer of plasma cells of the bone marrow.
“A caregiver and a patient are a team, like a coach and a quarterback,” says caregiver Deb Osborne. “You do a lot of work strategizing together beforehand, and then as the coach you send your quarterback into the action.
People diagnosed with precursor conditions that often lead to multiple myeloma currently have little way of gauging their risk of myeloma or knowing when, if ever, the disease might progress.
CAR T-cell therapy is a cancer treatment in which a patient’s immune system T cells are genetically modified to mount a more effective attack on cancer. As of May 2018, CAR T-cell therapy has been approved by the U.S. Food and Drug Administration as standard therapy for some adult patients with aggressive non-Hodgkin lymphoma that has relapsed after … Read more
Thanks to major advances in treatment in recent years, patients diagnosed with multiple myeloma today have a much greater life expectancy, even though the blood cancer isn’t curable. It’s possible to think of myeloma – a malignancy affecting antibody-producing immune cells – as a chronic disease with which some individuals can live for many years. … Read more
When Linda Solomon, a trained medical technologist, saw the results of her routine complete blood count in 2009, she knew it wasn’t good news. Solomon, then 61, was diagnosed with stage III multiple myeloma – and given three years to survive. Several rounds of chemotherapy, two stem cell transplants, and eight years later, Solomon is … Read more
A stem cell transplant can be a lifesaving treatment for patients with leukemia, lymphoma, multiple myeloma, or certain blood-related disorders. In many cases, however, transplants increase patients’ risk for an array of long-term health problems, often caused by the high doses of chemotherapy and/or radiation therapy used prior to the transplant. Dana-Farber’s Adult Stem Cell Survivorship … Read more
Treatment of blood-related, or hematologic, cancers is seizing on insights into the basic genetic wiring of cancer cells and the body’s system for finding and attacking those cells. Research presentations at the annual American Society of Hematology (ASH) meeting in December gave evidence of how broad, and rapid, the progress is. Targeted therapies, new combinations … Read more
In a recent Facebook Live webchat, Jacob Laubach, MD, MPP, Clinical Director of the Jerome Lipper Multiple Myeloma Center, discussed the different ways that patients can be treated with multiple myeloma, as well as exciting avenues of treatment, such as combination therapy.
Multiple myeloma is a type of cancer that begins in plasma cells — cells in the bone marrow, that, under normal circumstances, are involved in our immune defense system and produce antibodies. In multiple myeloma, too many plasma cells (myeloma cells) build up in the bone marrow. The presence of these tumor cells in the … Read more
With new research in immunotherapy and targeted therapy, treatment options for blood cancer patients are rapidly expanding. Combination therapies have also caused much excitement among researchers and physicians, and ongoing clinical trials are continuing to look at new strategies that use multiple drugs for fighting these diseases. In this Cancer Conversations podcast episode, Irene Ghobrial, … Read more
By Elise Renner There’s a 1-in-12 chance that this is the month yours or your loved one’s cancer is recognized—odds better than the survival rates for some of these diseases. Some months, like October, boast big names like breast cancer. Others, like September, are crowded with lesser-known branches of the disease. “Cancer apparel,” including ribbons … Read more
The world is divided between those who are sympathetic to their friends and family who have cancer and those who have cancer and are empathetic with each other, says Tom Brokaw, the former “NBC Nightly News” anchor. Brokaw, who was diagnosed with multiple myeloma in August 2013, shares his cancer story in the video below. … Read more
By Ethan Hawes “Having cancer in college doesn’t seem real.” That was my first thought when I received what would become life-changing news at the age of 22 as a senior at the University of Maine (Orono). My body went numb and tears started to form when my doctor told me I had multiple myeloma, … Read more